Marginal Zone Lymphoma >  
Marginal Zone Lymphoma abstracts - ASH 2012

Last update: 11/09/2012

MZL specific:

1. The Many Faces of Marginal Zone Lymphoma

2. Rituximab and Chlorambucil As First Line Therapy of Low-Grade Ocular Adnexal Lymphomas: Long Term Follow-up Results

3. Radiotherapy in Stage I and II Extranodal Marginal Zone B-Cell Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT): Analysis of the Surveillance, Epidemiology, and End Results (SEER) Database

4. Non-Follicular Low Grade B-Cell Lymphomas: Patterns of Presentation and Management with Comparative Prognostic Utility of IPI and FLIPI

Indolent:

1. Results of a Phase II Study of Lenalidomide in Combination with Rituximab for the Treatment of Indolent Non Follicular Non Hodgkin Lymphoma (NHL)

2. Fludarabine, Mitoxantrone and Rituximab (FMR) Regimen in Previously Untreated Patients with Indolent Non-Hodgkin Lymphoma: Efficacy, Safety and PET Data On 285 Patients

3. Bendamustine, Bortezomib, and Rituximab in Patients with Previously Untreated Low Grade Lymphoma: A Phase II Trial of the Sarah Cannon Research Institute

4. A Multicenter Phase II Clinical Trial of Rituximab Combined with Bortezomib (VELCADE®) Therapy for Untreated “High Tumor Burden” Indolent Non-Hodgkin Lymphoma (NHL)

5. Combinations of the Phosphatidylinositol 3-Kinase-Delta (PI3Kδ) Inhibitor Gs‑1101 (CAL-101) with Rituximab and/or Bendamustine Are Tolerable and Highly Active in Previously Treated, Indolent Non-Hodgkin Lymphoma: Results From a Phase I Study

6. Abexinostat (S78454 / PCI-24781), an Oral Pan-Histone Deacetylas (HDAC) Inhibitor in Patients with Refractory or Relapsed Hodgkin's Lymphoma, Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia. Results of a Phase I Dose-Escalation Study in 35 Patients

7. Lenalidomide and Rituximab for Untreated Indolent Lymphoma: Final Results of a Phase II Study

8. Phase 1 Study of Radiosensitization Using Bortezomib in Patients with Relapsed Non-Hodgkin’s Lymphoma Receiving Radioimmunotherapy

9. Number of PD-1+/CD8+ Cells in Peripheral Blood of Patients with Lymphoma Reflects Tumor Burden, Lymphoma Subtype, Disease Phase and Is Significantly Higher Compared to Healthy Volunteers

10. 90-Yttrium Ibritumomab Tiuxetan (Zevalin) and BEAM Chemotherapy (Z-BEAM) Vs BEAM for Autologous Stem Cell Transplantation in Lymphoma: Toxicity and Long Term Outcome From a Retrospective Multicentric Study of 123 Patients

11. A Phase 2 Study of Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) Plus Rituximab in Newly Diagnosed, Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma

12. Long Term Clinical Outcomes in Patients with Massive Splenomegaly and Non-Hodgkin’s Lymphoma Treated with Splenectomy

13. A Phase I Trial of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in Combination with Rituximab (R) and Bendamustine in Patients with Relapsed/Refractory Non-Hodgkin’s Lymphoma (NHL)

14. Phase I Trial of Combination Therapy with ⁹⁰y Ibritumomab Tiuxetan and Gemcitabine in Patients with Non-Hodgkin’s Lymphoma, Final Report

15. Non-Hodgkin Lymphoma II: Understanding the Indolent Lymphomas

Biology:

1. Defining the Malignant Epigenome in Non-Hodgkin Lymphoma

2. Clonal Selection in the Ontogeny and Evolution of Splenic Marginal Zone Lymphoma Confirming the Existence of Distinct Molecular Subtypes

3. Mutational Status of Splenic Marginal Zone Lymphoma Revealed by Whole Exome Sequencing

4. Strong Cell Surface Expression of the Toll-Like Receptor Homolog CD180 Identifies Circulating Cells of Marginal Zone Lymphoma From Other B-Cell Malignancies

5. Histologic Transformation in Marginal Zone Lymphomas

 

 

See also Other Ways to Help